Raytheon awarded $71 million in Navy contracts for missile systems
On February 24, 2025, NanoVibronix, Inc., a Delaware-incorporated company specializing in orthopedic and surgical devices, received shareholder approval for a reverse stock split and other significant proposals at a special meeting. The company, currently trading at $0.37 and near its 52-week low, has seen its stock decline over 63% in the past year, according to InvestingPro data. The reverse stock split, which will consolidate company shares at a ratio between 1-for-2 and 1-for-11 as decided by the Board, aims to boost the stock’s market price. The exact ratio will be determined by the Board and publicly announced. With a current market capitalization of just $1.4 million and strong revenue growth of 228% over the last twelve months, InvestingPro analysis suggests the stock is trading below its Fair Value.
The reverse stock split proposal received 1,560,759 votes in favor, 674,302 against, and 7,557 abstentions. Additionally, shareholders greenlighted the issuance of shares underlying certain warrants, in compliance with Nasdaq Listing Rule 5635(d), with 417,111 votes for, 290,431 against, and 6,803 abstentions. This issuance could result in an increase of over 20% of the common stock outstanding before the execution of the relevant Securities Exchange Agreement dated January 7, 2025.
A third proposal, allowing for the adjournment of the special meeting if necessary to solicit additional votes, was also approved with 1,755,445 votes for, 482,828 against, and 4,345 abstentions. However, the adjournment was not needed as sufficient votes were cast for the other proposals.
The special meeting’s record date was January 17, 2025, with over 6 million shares eligible to vote. The results represent a key step for NanoVibronix, traded on the Nasdaq Capital Market under the ticker symbol NAOV, as it continues to navigate the financial strategies to support its business operations. The information is based on a press release statement filed with the SEC. Looking ahead, NanoVibronix maintains a healthy balance sheet with more cash than debt, though InvestingPro analysis reveals 8 additional key insights about the company’s financial health and growth prospects available to subscribers.
In other recent news, NanoVibronix, Inc. announced the acquisition of ENvue Medical (TASE:BLWV) Holdings Corp., a provider of enteral feeding solutions. This strategic move, structured as a stock-for-stock transaction, is expected to enhance NanoVibronix’s position in the medical device sector. Concurrently, the company completed a private placement investment, issuing a senior convertible debenture with a principal amount of $500,000. In another development, NanoVibronix has completed the design phase for the next generation of its PainShield® and UroShield® devices, with improvements aimed at reducing costs and enhancing user experience. The company is set to move into the validation and testing phase for these devices.
Additionally, NanoVibronix entered into a securities exchange agreement with an institutional investor, issuing new shares and warrants in exchange for an outstanding warrant. This transaction aligns with regulatory frameworks and is subject to stockholder approval. The company also renewed its exclusive distribution agreement with Ultra Pain Products, Inc. for its PainShield device, securing a minimum purchase commitment of $12 million. These recent developments highlight NanoVibronix’s efforts to strengthen its market presence and expand its offerings in the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.